↓ Skip to main content

Levetiracetam add-on for drug-resistant focal epilepsy: an updated Cochrane Review

Overview of attention for article published in Cochrane database of systematic reviews, September 2012
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (82nd percentile)
  • Above-average Attention Score compared to outputs of the same age and source (58th percentile)

Citations

dimensions_citation
79 Dimensions

Readers on

mendeley
138 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Levetiracetam add-on for drug-resistant focal epilepsy: an updated Cochrane Review
Published in
Cochrane database of systematic reviews, September 2012
DOI 10.1002/14651858.cd001901.pub2
Pubmed ID
Authors

Gashirai K Mbizvo, Pete Dixon, Jane L Hutton, Anthony G Marson

Abstract

Epilepsy is an important neurological condition and drug resistance in epilepsy is particularly common in individuals with focal seizures. In this review, we summarise the current evidence regarding a new antiepileptic drug, levetiracetam, when used as add-on treatment for controlling drug-resistant focal epilepsy. This is an update to a Cochrane Review that was originally published in 2001.

Mendeley readers

The data shown below were compiled from readership statistics for 138 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 2 1%
Italy 2 1%
United Kingdom 1 <1%
Canada 1 <1%
Unknown 132 96%

Demographic breakdown

Readers by professional status Count As %
Student > Master 34 25%
Researcher 18 13%
Student > Postgraduate 13 9%
Student > Bachelor 11 8%
Student > Ph. D. Student 11 8%
Other 31 22%
Unknown 20 14%
Readers by discipline Count As %
Medicine and Dentistry 59 43%
Nursing and Health Professions 12 9%
Psychology 11 8%
Neuroscience 7 5%
Pharmacology, Toxicology and Pharmaceutical Science 6 4%
Other 14 10%
Unknown 29 21%

Attention Score in Context

This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 September 2017.
All research outputs
#2,749,112
of 15,827,677 outputs
Outputs from Cochrane database of systematic reviews
#5,502
of 11,293 outputs
Outputs of similar age
#25,338
of 154,789 outputs
Outputs of similar age from Cochrane database of systematic reviews
#36
of 87 outputs
Altmetric has tracked 15,827,677 research outputs across all sources so far. Compared to these this one has done well and is in the 81st percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 11,293 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 23.5. This one has gotten more attention than average, scoring higher than 50% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 154,789 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 82% of its contemporaries.
We're also able to compare this research output to 87 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 58% of its contemporaries.